Ironwood Pharmaceuticals Management
Management criteria checks 3/4
Ironwood Pharmaceuticals' CEO is Tom McCourt, appointed in Mar 2021, has a tenure of 3.75 years. total yearly compensation is $7.58M, comprised of 11% salary and 89% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth $2.28M. The average tenure of the management team and the board of directors is 3.3 years and 5.7 years respectively.
Key information
Tom McCourt
Chief executive officer
US$7.6m
Total compensation
| CEO salary percentage | 11.0% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 21
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
Oct 24Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Aug 16Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
Jun 27Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Jun 20Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$2m |
| Jun 30 2024 | n/a | n/a | US$9m |
| Mar 31 2024 | n/a | n/a | -US$1b |
| Dec 31 2023 | US$8m | US$834k | -US$1b |
| Sep 30 2023 | n/a | n/a | -US$952m |
| Jun 30 2023 | n/a | n/a | -US$917m |
| Mar 31 2023 | n/a | n/a | US$182m |
| Dec 31 2022 | US$8m | US$805k | US$175m |
| Sep 30 2022 | n/a | n/a | US$168m |
| Jun 30 2022 | n/a | n/a | US$173m |
| Mar 31 2022 | n/a | n/a | US$527m |
| Dec 31 2021 | US$9m | US$732k | US$528m |
| Sep 30 2021 | n/a | n/a | US$530m |
| Jun 30 2021 | n/a | n/a | US$509m |
| Mar 31 2021 | n/a | n/a | US$143m |
| Dec 31 2020 | US$3m | US$576k | US$106m |
| Sep 30 2020 | n/a | n/a | US$111m |
| Jun 30 2020 | n/a | n/a | US$97m |
| Mar 31 2020 | n/a | n/a | US$84m |
| Dec 31 2019 | US$5m | US$511k | US$59m |
| Sep 30 2019 | n/a | n/a | US$19m |
| Jun 30 2019 | n/a | n/a | -US$153m |
| Mar 31 2019 | n/a | n/a | -US$173m |
| Dec 31 2018 | US$2m | US$465k | -US$194m |
| Sep 30 2018 | n/a | n/a | -US$190m |
| Jun 30 2018 | n/a | n/a | -US$71m |
| Mar 31 2018 | n/a | n/a | -US$108m |
| Dec 31 2017 | US$2m | US$450k | -US$55m |
Compensation vs Market: Tom's total compensation ($USD7.58M) is above average for companies of similar size in the US market ($USD3.24M).
Compensation vs Earnings: Tom's compensation has been consistent with company performance over the past year.
CEO
Tom McCourt (67 yo)
3.8yrs
Tenure
US$7,583,270
Compensation
Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 08, 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since Jun...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Principal Financial Officer & Director | 3.8yrs | US$7.58m | 0.32% $ 2.3m | |
| Senior VP | 3.3yrs | US$2.44m | 0.079% $ 566.0k | |
| Chief Medical Officer | 5.9yrs | US$2.60m | 0.16% $ 1.1m | |
| Corporate Controller & Principal Accounting Officer | 5.7yrs | no data | 0.042% $ 302.3k | |
| VP & Global Head of Technical Operations | less than a year | no data | no data | |
| Vice President of Strategic Finance & Investor Relations | no data | no data | no data | |
| VP of Corporate Communications & Media Relations | 2.9yrs | no data | no data | |
| Vice President of Sales & Sales Excellence | 3.3yrs | no data | no data | |
| VP & Head of Clinical Development | 2.3yrs | no data | no data | |
| Director of Investor Relations | no data | no data | no data |
3.3yrs
Average Tenure
56.5yo
Average Age
Experienced Management: IRWD's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Principal Financial Officer & Director | 3.5yrs | US$7.58m | 0.32% $ 2.3m | |
| Independent Director | 4yrs | US$300.71k | 0.079% $ 563.1k | |
| Member of Pharmaceuticals Advisory Committee | no data | no data | no data | |
| Independent Director | 4.1yrs | US$300.69k | 0.098% $ 695.7k | |
| Independent Director | 5.7yrs | US$300.71k | 0.36% $ 2.5m | |
| Independent Director | 8.7yrs | US$310.71k | 0.12% $ 837.6k | |
| Member of Pharmaceutical Advisory Committee | 7.8yrs | no data | no data | |
| Independent Director | 5.7yrs | US$310.69k | 0.046% $ 324.6k | |
| Independent Chairman of the Board | 10.8yrs | US$335.71k | 0.10% $ 729.1k | |
| Independent Director | 5.7yrs | US$300.71k | 0.076% $ 537.9k | |
| Independent Director | 5.7yrs | US$305.71k | 0.091% $ 646.8k |
5.7yrs
Average Tenure
65yo
Average Age
Experienced Board: IRWD's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 05:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ironwood Pharmaceuticals, Inc. is covered by 37 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |